Benzinga's Top Pre-Market Gainers

Orexigen Therapeutics

surged 7.36% to $6.42 in the pre-market session. Orexigen projects to complete enrollment of patients required for the interim analysis of the Light Study in the first quarter. Abercrombie & Fitch Co

added 5.71% to $34.64 in the pre-market session. Abercrombie & Fitch's PEG ratio is 0.51. Questcor Pharmaceuticals

moved up 4.93% to $47.29 in the pre-market session. Questcor's trailing-twelve-month ROE is 59.92%. Mead Johnson Nutrition Company

soared 4.13% to $78.40 in the pre-market trading. The quality and safety of Mead Johnson's products were confirmed by the local office of the China AQSIQ.